2023 C-Suite Trends, Updates and the CFO Leadership Awards Recap
Steve Binder has been the chief financial officer at MannKind since July 2017.
July 30, 2023
Business
MannKind stock falls after news of Afrezza lawsuit
Nov. 5, 2010
The C-Suite: Trends. Updates. Visionaries. The CFO Leadership Awards.
Michael Castagna became CEO of MannKind and joined its board of directors in 2017, bringing 25+ years’ experience in healthcare, pharmaceuticals and biotechnology to the company’s product and medical device development strategy.
July 18, 2022
With a new deal to collaborate on an inhalable hypertension drug, the executives at Southern California drugmaker MannKind Corp. can breathe a little easier about the company’s finances.
Sept. 4, 2018
Hours after MannKind Corp. announced on Tuesday that Sanofi had pulled out of an agreement to license its Afrezza inhaled insulin, a MannKind executive said the Valencia company does not plan to sell the drug and will seek a new marketing partner.
Jan. 5, 2016
Alfred Mann, the billionaire entrepreneur and inventor behind several successful medical device companies, is stepping down as chief executive of MannKind Corp., a Valencia maker of inhaled insulin.
Jan. 12, 2015
Hakan Edstrom has stepped down as chief executive of the Valencia-based biotech company MannKind Corp., the company said Friday.
Nov. 20, 2015
Struggling drug developer MannKind Corp., the maker of an inhalable insulin treatment that’s so far posted disappointing sales, might be looking for a buyer.
Jan. 27, 2016
Less than two months after receiving approval for an inhalable form of insulin, MannKind Corp. agreed to license the drug to Paris-based Sanofi in a deal that could provide the Valencia company with $925 million.
Aug. 11, 2014
MannKind Corp., the company staking its future on inhaled insulin, said Thursday that its drug didn’t cause adverse lung effects in the last studies for U.S. regulatory approval.
Dec. 5, 2008